Galaxy Therapeutics Completes Enrollment in Pivotal SEAL IT IDE Trial

MILPITAS, Calif., Dec. 23, 2025 /PRNewswire/ -- Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced it has successfully completed enrollment in SEAL IT, its U.S. IDE trial evaluating the SEAL device for brain...

Read More